Wealthink AI-Innovation Capital Limited (1140.HK) is a Cayman Islands-incorporated investment holding company listed on the Main Board of The Stock Exchange of Hong Kong Limited that engages in cross-border and cross-sector investments across listed and unlisted enterprises, with a focus on China's fast-growing industries including technology, healthcare, fintech, education, and financial services; it builds diversified cross-cycle portfolios through private equity strategies with long-term core holdings such as 7.73% equity in iCarbonX Group Limited (digital health and AI-driven precision medicine), 30% equity in OPIM Holdings Limited (Asia's leading hedge fund platform managing over US$1.6 billion in assets), debt investments yielding 5-10% interest on loans to investment companies with tenures of 9 months to 2 years, fund investments like Qingdao Wanfeng Shidai Linghang Equity Investment Center (technology, media, telecom sectors) and others targeting cybersecurity, AI, semiconductors, fund investments in specialized SMEs, listed equity investments for short-term opportunities including GoFintech Quantum Innovation Limited (0290.HK), and artwork investments in imperial porcelain from the Ming Xuande Period and Qing Dynasty three reigns. The company, founded in 2002 and headquartered at Room 3910-13, 39/F, COSCO Tower, Grand Millennium Plaza, 183 Queen's Road Central, Hong Kong, derives majority revenue from Hong Kong followed by Mainland China and the United States, serving institutional and professional investors through customized syndicate solutions, interests, dividends, and capital appreciation. Recent strategic shifts include re-establishing a five-core investment framework in 2025 encompassing core-holding unlisted equity, debt, funds, listed equity, and artworks; new investments totaling HK$1,302.41 million and divestments of HK$990.38 million for the six months ended 30 September 2025; significant expansion in artwork holdings to HK$1,211.10 million; a May 2025 breakthrough announcement by iCarbonX in silicon-based multi-omics chips and AI modeling; and a November 2025 update confirming no grants or exercises under its share option scheme with 183,839,600 options available.